A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

There are obesity therapies ahead of the queue in Novo Nordisk’s pipeline, including an oral formulation of semaglutide, due to report phase 3 results later this year, as well as CagriSema ...

Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

I’d recommend checking out my last article, where I took a deeper look at some of Novo Nordisk’s most promising pipeline treatments for diabetes, like IcoSema or oral semaglutide. Obesity ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk ... and 2.4 mg semaglutide for ...